A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma

Temozolomide (TMZ) was used for the treatment of glioblastoma (GBM) for over a decade, but its treatment benefits are limited by acquired resistance, a process that remains incompletely understood. Here we report that an enhancer, located between the promoters of marker of proliferation Ki67 (MKI67)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaoyue, Zhang, Minjie, Gan, Haiyun, Wang, Heping, Lee, Jeong-Heon, Fang, Dong, Kitange, Gaspar J., He, Lihong, Hu, Zeng, Parney, Ian F., Meyer, Fredric B., Giannini, Caterina, Sarkaria, Jann N., Zhang, Zhiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063898/
https://www.ncbi.nlm.nih.gov/pubmed/30054476
http://dx.doi.org/10.1038/s41467-018-05373-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063898/
https://www.ncbi.nlm.nih.gov/pubmed/30054476
http://dx.doi.org/10.1038/s41467-018-05373-4

Ejemplares similares